Verve Therapeutics, Inc. (VERV) Retained Earnings (Accumulated Deficit) USD 2020 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Verve Therapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from 2020 to 2024.
  • Verve Therapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending March 31, 2024 was -$593 M, a 49.7% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 -$593 M -$197 M -49.7% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$544 M -$200 M -58.1% Dec 31, 2023 10-Q 2024-05-08
Q3 2023 -$496 M -$193 M -63.6% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$450 M -$192 M -74.5% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$396 M -$179 M -82.6% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 -$344 M -$157 M -84.2% Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$303 M -$148 M -94.9% Sep 30, 2022 10-Q 2022-11-07
Q2 2022 -$258 M -$125 M -94.3% Jun 30, 2022 10-Q 2022-08-09
Q1 2022 -$217 M Mar 31, 2022 10-Q 2022-05-10
Q4 2021 -$187 M -$120 M -181% Dec 31, 2021 10-K 2023-03-02
Q3 2021 -$156 M Sep 30, 2021 10-Q 2021-11-10
Q2 2021 -$133 M Jun 30, 2021 10-Q/A 2021-08-16
Q4 2020 -$66.5 M Dec 31, 2020 10-K 2022-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.